ROIV — Roivant Sciences Ltd. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $38.71
- YTD price return
- +78.39%
- YTD total return
- +78.39%
- Market cap
- 28B
- Enterprise value
- 24.5B
- Shares outstanding
- 724.6M
- 52W low
- $19.96
- 52W high
- $42.50
- From 52W high
- -8.92%
- From 52W low
- +93.94%
- 52W range
- 83%$19.96–$42.50
- Beta
- 1.12
Volume
- Rel volume
- 1.10×
- 30D volume
- 7.7M
- 30D $ vol
- 288.4M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- −$41.7M
- Insider net 3M
- −$63.9M
- Insider net 1Y
- −$526.6M
Form 4 transactions by trade date, as filed; latest on file 2026-11-11.
Fundamentals
- Sales (ttm)
- 41.1M
- Sales/share
- $0.06
- EPS (ttm)
- -$0.48
- FCF (ttm)
- -33.3M
- FCF/share
- -$0.05
- Book value/share
- $5.55
- Net margin
- -838.21%
- ROE
- -8.57%
- ROA
- -6.92%
- Current ratio
- 15.56
Growth (CAGR, ttm) · 10Y
- Sales
- +102.18%-18.08%-6.38%n/a
- Shares
- +4.18%-3.40%+1.14%n/a
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- +94.07%-16.47%-7.08%n/a
- Book value/share
- -11.55%+67.52%+13.27%n/a
- Price
- +88.36%+62.79%+36.60%n/a
- Total return
- +88.36%+62.79%+36.60%n/a
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -80.3×
- Fwd P/E
- -24.5×
- P/S (ttm)
- 682.7×
- P/B (mrq)
- 7.0×
- EV/Sales (ttm)
- 597.1×
- FCF yield (ttm)
- -0.12%
- Buyback yield (realized, 1y)
- -4.18%
- Shareholder yield (realized, 1y)
- -4.18%
- Buyback yield (cash, ttm)
- 1.80%
- Shareholder yield (cash, ttm)
- 1.80%
Vs own 10Y history
- P/S
- 79th
- P/B
- 90th
Bar = where today’s multiple sits in ROIV’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-17#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y n/m5Y n/mYoY n/mEPS (diluted)
5Y n/m5Y n/mYoY n/mFree cash flow
5Y n/m5Y n/mYoY n/mTTM: operating cash flow −$36.4M, capex −$3M
Q2 2026: operating cash flow $594.4M, capex −$208K
Shares (diluted)
5Y +10.1%5Y +10.1%YoY +6.1%Net income
5Y n/m5Y n/mYoY n/mAbout Roivant Sciences#
Data provided bySource: Twelve DataRoivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines and technologies through a portfolio of specialized subsidiary companies. Roivant Sciences Ltd. operates across immunology, dermatology, and other high-unmet-need therapeutic areas, with current work spanning commercial products and clinical-stage candidates. Its business model emphasizes creating focused operating companies to advance individual drug programs, support partnering activities, and incubate complementary health technology initiatives. The company’s current product and pipeline portfolio includes therapies for autoimmune and inflammatory diseases, as well as treatments being studied in areas such as dermatologic conditions, uveitis, pulmonary hypertension, and rare diseases. Roivant Sciences Ltd. plays a distinctive role in the healthcare market by combining drug development expertise with an asset-centric structure designed to move promising medicines toward commercialization.
London, United Kingdom·721 employees·Biotechnology·roivant.com·As of Oct 28, 2026
Recent filings#
- Nov 11Insider sale · Pulik Richard (CFO) sold 300,000 shares for $12.5M on 2 days since Nov 10
- Nov 9Earnings · Earnings release — EPS −$0.30 vs −$0.52 est. (+42.3%); revenue $35.1M (+2136% y/y) 4.6%
- Oct 218-K · Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
- Sep 88-K · Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
- Aug 278-K · Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
ETFs holding ROIV#
23 of the 193 ETFs ChartRow carries live hold ROIV. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| IBB | iShares Biotechnology ETF | 1.4% |
| XBI | SPDR S&P Biotech ETF | 1.2% |
| VBK | Vanguard Small-Cap Growth ETF | 0.5% |
| IJH | iShares Core S&P Mid-Cap ETF | 0.4% |
| MDY | SPDR S&P MidCap 400 ETF Trust | 0.4% |
| VHT | Vanguard Health Care ETF | 0.2% |
| VB | Vanguard Small-Cap ETF | 0.2% |
| VXF | Vanguard Extended Market ETF | 0.2% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +12.61% | -1.13% |
| JNJ | Johnson & Johnson | +9.05% | -1.36% |
| ABBV | AbbVie Inc. | +2.59% | -0.59% |
| MRK | Merck & Co. Inc. | -1.77% | -0.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -2.93% | -5.42% |
| NVS | Novartis AG | +5.65% | -0.67% |
| TMO | Thermo Fisher Scientific Inc. | -0.47% | -0.66% |
| AMGN | Amgen Inc. | +5.88% | -0.95% |
